W.LawitzE.BugianesiE.et al (2024)
Whether GLP-1s are covered by insurance has huge implications nationally because the drugs, which were first approved to treat diabetes and later obesity, are also being studied for possible future treatment of a wide range of other conditions, from kidney disease to Alzheimers to substance abuse disorder, thus accelerating demand
The medical trial involved 48 individuals with AUD, most of whom had a body mass index (BMI) over 30
By helping patients tolerate treatments and making sure treatments are as effective as possible, GSH can thus improve the quality of life and disease outcomes
60 bis 100 Euro, fr einen Monat kommen somit bei den blichen wchentlichen Anwendungen etwa 300 Euro zusammen
Efficacy of dulaglutide as a first injectable option for patients with type 2 diabetes: a post-hoc pooled analysis